image
Healthcare - Medical - Devices - NASDAQ - US
$ 3.58
-5.03 %
$ 3.87 M
Market Cap
-0.47
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one HSCS stock under the worst case scenario is HIDDEN Compared to the current market price of 3.58 USD, Heart Test Laboratories, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one HSCS stock under the base case scenario is HIDDEN Compared to the current market price of 3.58 USD, Heart Test Laboratories, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one HSCS stock under the best case scenario is HIDDEN Compared to the current market price of 3.58 USD, Heart Test Laboratories, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart HSCS

image
$4.6$4.6$4.4$4.4$4.2$4.2$4.0$4.0$3.8$3.8$3.6$3.6$3.4$3.4$3.2$3.2$3.0$3.0$2.8$2.8$2.6$2.615 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
18.6 K REVENUE
261.17%
-6.31 M OPERATING INCOME
-3.15%
-6.61 M NET INCOME
-3.95%
-6.07 M OPERATING CASH FLOW
-5.14%
-125 K INVESTING CASH FLOW
-584.24%
10.3 M FINANCING CASH FLOW
58.29%
0 REVENUE
0.00%
-2.37 B OPERATING INCOME
-119367.64%
-2.54 M NET INCOME
99.94%
-1.62 M OPERATING CASH FLOW
99.96%
-15.7 K INVESTING CASH FLOW
99.76%
180 K FINANCING CASH FLOW
-99.99%
Balance Sheet Heart Test Laboratories, Inc.
image
Current Assets 7.35 M
Cash & Short-Term Investments 5.81 M
Receivables 0
Other Current Assets 1.55 M
Non-Current Assets 2.15 M
Long-Term Investments 0
PP&E 560 K
Other Non-Current Assets 1.59 M
61.11 %16.27 %5.89 %16.72 %Total Assets$9.5m
Current Liabilities 1.75 M
Accounts Payable 448 K
Short-Term Debt 602 K
Other Current Liabilities 701 K
Non-Current Liabilities 434 K
Long-Term Debt 434 K
Other Non-Current Liabilities 0
20.50 %27.55 %32.08 %19.86 %Total Liabilities$2.2m
EFFICIENCY
Earnings Waterfall Heart Test Laboratories, Inc.
image
Revenue 18.6 K
Cost Of Revenue 6.08 K
Gross Profit 12.5 K
Operating Expenses 6.32 M
Operating Income -6.31 M
Other Expenses 299 K
Net Income -6.61 M
1m1m00(1m)(1m)(2m)(2m)(3m)(3m)(4m)(4m)(5m)(5m)(6m)(6m)(7m)(7m)19k(6k)13k(6m)(6m)(299k)(7m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
67.31% GROSS MARGIN
67.31%
-33901.99% OPERATING MARGIN
-33901.99%
-35511.87% NET MARGIN
-35511.87%
-90.27% ROE
-90.27%
-69.51% ROA
-69.51%
-75.49% ROIC
-75.49%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Heart Test Laboratories, Inc.
image
00(1m)(1m)(2m)(2m)(3m)(3m)(4m)(4m)(5m)(5m)(6m)(6m)(7m)(7m)Jul '20Jul '2020212021Jul '21Jul '2120222022Jul '22Jul '2220232023Jul '23Jul '2320242024
Net Income -6.61 M
Depreciation & Amortization 95.1 K
Capital Expenditures -125 K
Stock-Based Compensation 405 K
Change in Working Capital -504 K
Others 171 K
Free Cash Flow -6.2 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Heart Test Laboratories, Inc.
image
HSCS has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 10
6. Ownership
Insider Ownership Heart Test Laboratories, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis Southlake, TX, June 04, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (“AI”) powered medical technology company focused on advancing the capabilities of ECGs/EKGs for the earlier detection of heart disease, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Breakthrough Device designation for its Aortic Stenosis (“AS”) ECG algorithm. Aortic Stenosis is one of the most serious and common heart valve diseases, often progressing silently and leading to severe, life-threatening outcomes if left undetected. globenewswire.com - 1 week ago
HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone Southlake, TX, May 29, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (“AI”)-powered medical technology company focused on transforming ECGs/EKGs to enable earlier detection of heart disease, today announced the signing of its first commercial customer for the MyoVista Insights™ platform: Westcliffe Health Innovations, based in the United Kingdom. globenewswire.com - 2 weeks ago
HeartSciences' CEO Andrew Simpson to Present at Emerging Growth Conference 82 on Wednesday, May 21, 2025 Southlake, TX, May 20, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc . (Nasdaq:HSCS) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that Chief Executive Officer Andrew Simpson will deliver a live presentation and participate in a Q&A session at the Emerging Growth Conference 82. globenewswire.com - 3 weeks ago
HeartSciences to Host Investor Webinar and Q&A on Wednesday May 14, 2025 - Featuring CEO Andrew Simpson Southlake, TX, May 08, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq:HSCS) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that it will host a live investor webinar on Wednesday, May 14, 2025, at 2:00 p.m. EDT | 11:00 a.m. PDT, featuring a presentation and Q&A session with CEO Andrew Simpson. globenewswire.com - 1 month ago
HeartSciences Adds Prominent Key Advisors to its Scientific Advisory Board Southlake, TX, May 07, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc.  (Nasdaq:HSCS) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Dr. Girish Nadkarni, MD, Dr. Joshua Lampert, MD, and Dr. Akhil Vaid, MBBS, to its Scientific Advisory Board. These appointments underscore HeartSciences' commitment to advancing and transforming data-driven AI-ECG technology. globenewswire.com - 1 month ago
HeartSciences Announces Launch of MyoVista Insights™ Platform and Related Early Adopter Program Southlake, TX, May 01, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence ("AI")-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced today that it has launched the MyoVista InsightsTM platform and related early adopter program for select reference sites. globenewswire.com - 1 month ago
HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2025 Financial Results Southlake, TX, March 13, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (“AI”)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the third quarter fiscal 2025 ended January 31, 2025 and provided a business update. globenewswire.com - 3 months ago
HeartSciences Inc. Engages Integrous Communications to Enhance Investor Communications Southlake, TX, March 10, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (“AI”)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced today that it has engaged Integrous Communications, a premier investor relations firm, to enhance communication channels with investors and the investment community. Under the expert guidance of Integrous Communications, HeartSciences will embark on a comprehensive investor relations program, benefiting from Integrous Communications' proven track record in collaborating with leading medical companies to develop and execute an effective investor relations program. globenewswire.com - 3 months ago
HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results Southlake, TX, Dec. 16, 2024 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the second quarter fiscal 2025 ended October 31, 2024 and provided a business update. globenewswire.com - 6 months ago
HeartSciences' AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement Southlake, TX, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that the Centers for Medicare & Medicaid Services (CMS) has included AI-ECG technology in the 2025 Hospital Outpatient Prospective Payment System (OPPS) final rule under assignment APC 5734. This approval would allow outpatient settings to receive reimbursement for HeartSciences' MyoVista® wavECGTM algorithm and MyoVista® InsightsTM low ejection fraction algorithm, upon FDA clearance. The payment rate is expected to be $125. globenewswire.com - 7 months ago
HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit Southlake, TX, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc.  d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced today that Company CEO Andrew Simpson has been invited to participate in the 2024 Maxim Healthcare Virtual Summit, presented by Maxim Group LLC and hosted by M-Vest, from Tuesday October 15 to Thursday October 17, 2024. globenewswire.com - 8 months ago
HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results Southlake, TX, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the first quarter fiscal 2025 ended July 31, 2024 and provided a business update. globenewswire.com - 9 months ago
8. Profile Summary

Heart Test Laboratories, Inc. HSCS

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 3.87 M
Dividend Yield 0.00%
Description Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional 12-lead resting ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.
Contact 550 Reserve Street, Southlake, TX, 76092-1552 https://heartsciences.com
IPO Date June 16, 2022
Employees 15
Officers Ms. Danielle Watson Chief Financial Officer & Treasurer Mr. Mark T. Hilz Chief Operating Officer, Secretary & Director Mr. Andrew Simpson Chief Executive Officer, President & Chairman of the Board of Directors